Discounts prompt Scots yes to fund Intermune's Esbriet and Gilead's Stribild
This article was originally published in Scrip
Executive Summary
Price discounts have helped Intermune and Gilead secure reimbursement recommendations from Scotland's health technology appraisal body, the Scottish Medicines Consortium, for orphan drug Esbriet (pirfenidone) and Stribald (elvitegravir plus cobicistat plus emtricitabine plus tenofovir disoproxil) for HIV-1 patients.